Pediatric TCM Market Heats Up as Top 20 List Released Amid Industry Restructuring

(May 21, 2020) Price Slashes of Up to 80%! Sodium Bicarbonate Ringer's Injection from Hengrui Medicine and Kelun Pharmaceutical Simultaneously Reduced; The “Butterfly Effect” of Volume-Based Procurement Arrives! Layoffs and Structural Adjustments at Pharmaceutical Companies May Surge; Impressive Data for PD-L1 Antibody Combined with Bevacizumab as First-Line Treatment for Liver Cancer; Inclusion of Internet Healthcare in Medical Insurance to Accelerate Outpatient Payment Reform...(Click the title to access the original text)

[Pharma First Hour]Remdesivir Poised for Commercial Launch: What Are Gilead’s Odds of Success?

Recently, SVB Leerink analyst Geoffrey Porges released an investor report following a conversation with Gilead Sciences’ Chief Financial Officer Andrew Dickinson: The 1.5 million doses of remdesivir donated free of charge by Gilead are expected to be exhausted by June or early July this year, after which the company will transition to commercial sales. A recent cost-effectiveness analysis suggested that the medication cost per patient is approximately $30,000, and Gilead will charge only a fraction of this amount.

Toutiao Jun:The Institute for Clinical and Economic Review set the fair price at $4,460.

【CyberBlue】Up to 80% Price Cut! Hengrui Medicine/Kelun Pharmaceutical’s Sodium Bicarbonate Ringer’s Injection Simultaneously Reduced in Price

Recently, the Heilongjiang Provincial Healthcare Security Administration issued a notice acknowledging the voluntary price reduction applications submitted by companies such as Jiangsu Hengrui Medicine Co., Ltd. and Sichuan Kelun Pharmaceutical Co., Ltd. Among these, the price of Hengrui’s Sodium Bicarbonate Ringer’s Injection (500 ml) was reduced from 357.25 yuan to 98 yuan, representing a 72.5% decrease; the price of Gabapentin Capsules (0.1 g) was reduced from 25.41 yuan to 24.46 yuan.

Toutiao Jun:"Hengrui and Kelun simultaneously reducing prices by nearly 80% is more conducive to both companies capturing market share."

[Eight O’Clock Health News]What Wind Has Blown Internet Tycoons to the National Healthcare Security Administration?

Starting in April, several restless internet moguls set their sights with surprising uniformity on a gray building located on Letan North Street in Xicheng District, Beijing. What drew them was a department established just two years prior within that building: the National Healthcare Security Administration. Liu Qiangdong, who has rarely made public appearances in recent years, also paid a visit.

Toutiao Jun:The pandemic has opened up opportunities for internet-based healthcare.

【E-Pharma Manager】The “Butterfly Effect” of Volume-Based Procurement Is Here! Layoffs and Structural Adjustments at Pharmaceutical Companies May Surge

Recently, industry self-media outlets reported that a domestic pharmaceutical company, due to the delayed online listing of its product, compounded by the impact of the pandemic and competition from similar products, experienced unsatisfactory market development and sales in Henan Province, falling far short of the company’s and regional division’s expected targets. Consequently, the pharmaceutical company has decided to transition all operations for this product in the Henan market to a contracting model starting in May.

Toutiao Jun:The immediate reason for the team restructuring was ineffective product promotion.

[PharmaCube]PD-L1 Antibody Combined with Bevacizumab: Stunning First-Line Treatment Data for Liver Cancer

Recently, clinical study results published in the NEJM showed that the combination of the PD-L1 antibody atezolizumab and the VEGF antibody bevacizumab improved overall survival outcomes for this patient population, while reducing the risk of death by 42%. This combination therapy also reduced the risk of cancer progression by 41%, and more than doubled the proportion of patients whose tumors shrank or disappeared completely.

Toutiao Jun:This is also the first successful combination therapy regimen.

【Villager's Diary】Inclusion of Internet Healthcare in Medical Insurance Will Accelerate Outpatient Payment Reform

The inclusion of internet-based healthcare services in the national health insurance system poses significant challenges to the health insurance payment framework. These challenges extend beyond service regulation, exerting substantial pressure on outpatient reimbursement mechanisms, which in turn will accelerate reforms in the outpatient payment system.

Toutiao Jun:Internet healthcare will continue to concentrate in large hospitals rather than penetrate into primary care institutions.

[Yaozhi.com]What Changes Will the “Halftime Break” Bring to the Healthcare Industry in the “Second Half”?

Much like a basketball game, the “first half” was ambushed by the sudden onset of the COVID-19 pandemic, disrupting the rhythm of domestic production and daily life in China and further impacting the pace of economic activity. Facing the “second half,” marked by the resumption of work and production, critical questions remain: How should we proceed? In which direction should we head? At this juncture, the “halftime break” represented by the Two Sessions becomes particularly crucial; the key to victory in the second half may well hinge on a single directive from the “coach.”

Toutiao Jun:Vaccines are the only option to end the epidemic.

[Menet]Top 20 Pediatric Chinese Proprietary Medicines Released! 18 Brands Exceed RMB 100 Million in Sales, 4 Products Grow by Over 30%

Recently, the pediatric drug market has seen further positive developments. The Center for Drug Evaluation (CDE) officially released the "Technical Guidelines for Real-World Evidence Supporting Pediatric Drug Development and Review (Draft for Comment)." These guidelines apply to all categories of pediatric medications, including chemical drugs, traditional Chinese medicines (TCM), and biological products. Data from Menet shows that in 2019, sales of TCM pediatric drugs at public medical institutions in China reached nearly RMB 9 billion, representing a year-on-year increase of 11.61%. Among the top 20 products, 13 were exclusive products; four products, including Xiao'er Kechuanling Oral Liquid and Xiao'er Feire Kechuan Granules, each saw sales growth exceeding 30%. Among the top 20 brands, Jichuan Pharmaceutical's Xiao'er Chiqiao Qingre Granules have consistently ranked first for many years, with sales hitting a new high of RMB 1.476 billion in 2019. Meanwhile, Jiangsu Kanion Pharmaceutical's Jinzhen Oral Liquid surpassed RMB 500 million in sales.

Toutiao Jun:Kaihoujian Spray (Pediatric Version) Sales Continue to Rise.